Yonsei University

This study is testing a treatment plan for people with operable non-small cell lung cancer. Patients receive an immunotherapy drug (durvalumab) before surgery, followed by surgery, and then more durvalumab plus standard chemotherapy after surgery. The main goal is to see how much…

This study looks at which of two common types of diabetes medicine is better at preventing major heart problems in people who have both diabetes and a recent heart attack. Researchers will analyze the health records of 200,000 patients in Korea to compare outcomes for those takin…

This study is observing how well a new type of drug-coated stent works for people with long blockages in their heart arteries. The stent, called Cre8, is designed without polymer and slowly releases medication. Researchers are following 300 patients with blockages longer than 30m…

This study is testing whether giving a combination of treatments before surgery can help people with a specific type of advanced head and neck cancer. The treatment combines an investigational HPV vaccine with one or two immunotherapy drugs. The goal is to see if this approach ca…

This study is testing a drug called T-DXd (Trastuzumab deruxtecan) for people with a specific type of advanced lung cancer that has spread to the brain. The main goal is to see how well the drug controls the cancer in the brain and how long it keeps it from getting worse. It will…

This study aims to find out which of two powerful cholesterol-lowering drug combinations is better for people who have had a heart stent placed. Researchers will compare how well patients tolerate each combination and how effectively they keep 'bad' cholesterol at a very low targ…

This study is testing a three-drug combination (Lazertinib, Pemetrexed, and Carboplatin) for people with a specific type of advanced non-small cell lung cancer. It is for patients whose cancer has started growing again after being treated with the drug Lazertinib alone. The main …

This study aims to find better ways to predict which patients with advanced head and neck cancer will benefit from the immunotherapy drug nivolumab. Researchers will analyze blood and tumor samples from 50 patients to look for biological markers linked to treatment success. The g…